R. Gibson, J. Burns, and B. Ramsey, Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.8, pp.918-51, 2003.
DOI : 10.1164/rccm.200304-505SO

M. Alhede, T. Bjarnsholt, M. Givskov, and M. Alhede, Pseudomonas aeruginosa Biofilms, Adv Appl Microbiol, vol.86, pp.1-40, 2014.
DOI : 10.1016/B978-0-12-800262-9.00001-9

A. Folkesson, L. Jelsbak, L. Yang, H. Johansen, O. Ciofu et al., Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective, Nature Reviews Microbiology, vol.176, issue.12, pp.841-51, 2012.
DOI : 10.1038/nrmicro2907

C. Winstanley and J. Fothergill, infections, FEMS Microbiology Letters, vol.290, issue.1, pp.1-9, 2009.
DOI : 10.1111/j.1574-6968.2008.01394.x

C. Cigana, N. Lore, M. Bernardini, and A. Bragonzi, Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa Pneumonia, J Biomed Biotechnol, p.852513, 2011.
DOI : 10.1155/2011/852513

URL : https://hal.archives-ouvertes.fr/pasteur-00975374

E. Breidenstein, C. De-la-fuente-nunez, and R. Hancock, Pseudomonas aeruginosa: all roads lead to resistance, Trends in Microbiology, vol.19, issue.8, pp.419-445, 2011.
DOI : 10.1016/j.tim.2011.04.005

T. Strateva and D. Yordanov, Pseudomonas aeruginosa ? a phenomenon of bacterial resistance, Journal of Medical Microbiology, vol.58, issue.9, pp.1133-1181, 2009.
DOI : 10.1099/jmm.0.009142-0

N. Hoiby, O. Ciofu, and T. Bjarnsholt, biofilms in cystic fibrosis, Future Microbiology, vol.5, issue.11, pp.1663-74, 2010.
DOI : 10.2217/fmb.10.125

H. Johansen and P. Gotzsche, Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis, Cochrane Database Syst Rev, vol.8, p.1399, 2015.

K. Grimwood, J. Kyd, S. Owen, H. Massa, and A. Cripps, infection, Human Vaccines & Immunotherapeutics, vol.67, issue.1, pp.14-20, 2015.
DOI : 10.1128/IAI.74.2.968-974.2006

G. Priebe and J. Goldberg, Vaccines for Pseudomonas aeruginosa, Expert Rev Vaccines, vol.13, pp.507-526, 2014.
DOI : 10.1007/978-1-4615-0053-7_17

I. Delany, R. Rappuoli, D. Gregorio, and E. , Vaccines for the 21st century, EMBO Molecular Medicine, vol.6, pp.708-728, 2014.
DOI : 10.1002/emmm.201403876

S. Worgall, ?, Future Microbiology, vol.7, issue.12, pp.1333-1338, 2012.
DOI : 10.2217/fmb.12.106

A. Sharma, A. Krause, and S. Worgall, Recent developments for Pseudomonas vaccines, Human Vaccines, vol.3, issue.10, pp.999-1011, 2011.
DOI : 10.1016/j.virol.2008.04.016

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360073

G. Doring and G. Pier, Vaccines and immunotherapy against Pseudomonas aeruginosa, Vaccine, vol.26, issue.8, pp.1011-1035, 2008.
DOI : 10.1016/j.vaccine.2007.12.007

G. Pier, Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen, Carbohydrate Research, vol.338, issue.23, pp.2549-56, 2003.
DOI : 10.1016/S0008-6215(03)00312-4

I. Lin, T. Van, and P. Smooker, Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery, Vaccines, vol.58, issue.4, pp.940-72, 2015.
DOI : 10.1016/S0168-3659(01)00340-6

URL : http://doi.org/10.3390/vaccines3040940

C. Locht and N. Mielcarek, Live attenuated vaccines against pertussis, Expert Review of Vaccines, vol.13, issue.9, pp.1147-58, 2014.
DOI : 10.1586/14760584.2014.942222

G. Priebe, G. Meluleni, F. Coleman, J. Goldberg, and G. Pier, Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant, Infection and Immunity, vol.71, issue.3, pp.1453-61, 2003.
DOI : 10.1128/IAI.71.3.1453-1461.2003

W. Wu, J. Huang, B. Duan, D. Traficante, H. Hong et al., Pneumonia, American Journal of Respiratory and Critical Care Medicine, vol.186, issue.5, pp.420-427, 2012.
DOI : 10.1164/rccm.201202-0182OC

D. Brockstedt, K. Bahjat, M. Giedlin, W. Liu, M. Leong et al., Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity, Nature Medicine, vol.166, issue.8, pp.853-60, 2005.
DOI : 10.1046/j.1365-2958.2002.03072.x

A. Sancar and G. Sancar, DNA Repair Enzymes, Annual Review of Biochemistry, vol.57, issue.1, pp.29-67, 1988.
DOI : 10.1146/annurev.bi.57.070188.000333

S. Wollowitz, Fundamentals of the psoralen-based Helinx? technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, Seminars in Hematology, vol.38, pp.4-11, 2001.
DOI : 10.1016/S0037-1963(01)90118-0

T. Dubensky, J. Skoble, J. Lauer, P. Brockstedt, and D. , Killed but metabolically active vaccines. Current opinion in biotechnology, 2012.
DOI : 10.1016/j.copbio.2012.04.005

J. Skoble, J. Beaber, Y. Gao, J. Lovchik, L. Sower et al., Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax, Infection and Immunity, vol.77, issue.4, pp.1649-63, 2009.
DOI : 10.1128/IAI.00530-08

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663168

L. Gouellec, A. Chauchet, X. Laurin, D. Aspord, C. Verove et al., A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy, Molecular Therapy, vol.21, issue.5, pp.1076-86, 2013.
DOI : 10.1038/mt.2013.41

URL : https://hal.archives-ouvertes.fr/hal-00813378

L. Gouellec, A. Chauchet, X. Polack, B. Buffat, L. Toussaint et al., Bacterial vectors for active immunotherapy reach clinical and industrial stages, Human Vaccines & Immunotherapeutics, vol.55, issue.10, pp.1454-1462, 2012.
DOI : 10.1038/nrc2934

URL : https://hal.archives-ouvertes.fr/hal-00813376

X. Chauchet, D. Hannani, S. Djebali, D. Laurin, B. Polack et al., Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery, Molecular Therapy - Oncolytics, vol.3, p.16033, 2016.
DOI : 10.1038/mto.2016.33

URL : https://hal.archives-ouvertes.fr/hal-01463683

O. Epaulard, B. Toussaint, L. Quenee, M. Derouazi, N. Bosco et al., Anti-tumor Immunotherapy via Antigen Delivery from a Live Attenuated Genetically Engineered Pseudomonas aeruginosa Type III Secretion System-Based Vector, Molecular Therapy, vol.14, issue.5, pp.656-61, 2006.
DOI : 10.1016/j.ymthe.2006.06.011

URL : https://hal.archives-ouvertes.fr/inserm-00144349

L. Quenee, D. Lamotte, and B. Polack, Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa, BioTechniques, vol.38, issue.1, pp.63-70, 2005.
DOI : 10.2144/05381ST01

URL : https://hal.archives-ouvertes.fr/hal-00399228

C. Moser, H. Johansen, Z. Song, H. Hougen, J. Rygaard et al., H/HeN mice, APMIS, vol.254, issue.7-12, pp.838-880, 1997.
DOI : 10.1111/j.1699-0463.1997.tb05092.x

M. Stevenson, T. Kondratieva, A. Apt, M. Tam, and E. Skamene, In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid Pseudomonas aeruginosa, Clinical & Experimental Immunology, vol.93, issue.Suppl., pp.98-105, 1995.
DOI : 10.1111/j.1365-2249.1995.tb03478.x

L. Liguori and J. Lenormand, Chapter 11 Production of Recombinant Proteoliposomes for Therapeutic Uses, Methods Enzymol, vol.465, pp.209-232, 2009.
DOI : 10.1016/S0076-6879(09)65011-4

D. Langford, A. Bailey, M. Chanda, S. Clarke, T. Drummond et al., Coding of facial expressions of pain in the laboratory mouse, Nature Methods, vol.57, issue.6, pp.447-456, 2010.
DOI : 10.1016/j.neuron.2009.02.015

A. Hauser, The type III secretion system of Pseudomonas aeruginosa: infection by injection, Nature Reviews Microbiology, vol.67, issue.9, pp.654-65, 2009.
DOI : 10.1038/nrmicro2199

J. Audia, A. Lindsey, N. Housley, C. Ochoa, C. Zhou et al., In the Absence of Effector Proteins, the Pseudomonas aeruginosa Type Three Secretion System Needle Tip Complex Contributes to Lung Injury and Systemic Inflammatory Responses, PLoS ONE, vol.5, issue.11, p.81792, 2013.
DOI : 10.1371/journal.pone.0081792.s005

C. Milla, J. Chmiel, F. Accurso, D. Vandevanter, M. Konstan et al., airway infection, Pediatric Pulmonology, vol.29, issue.7, pp.650-658, 2014.
DOI : 10.1002/ppul.22890

G. Gicquel, Full virulence of Pseudomonas aeruginosa requires OprF, Infect Immun, vol.79, pp.1176-86, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00858403

L. Mutharia, T. Nicas, and R. Hancock, Outer Membrane Proteins of Pseudomonas aeruginosa Serotype Strains, Journal of Infectious Diseases, vol.146, issue.6, pp.770-779, 1982.
DOI : 10.1093/infdis/146.6.770

J. Liu, Y. Feng, K. Yang, Q. Li, L. Ye et al., infection in mice, FEMS Immunology & Medical Microbiology, vol.61, issue.2, pp.179-88, 2011.
DOI : 10.1111/j.1574-695X.2010.00764.x

D. Boeck, K. Amaral, and M. , Available from: http://www.vaincrelamuco.org/sites/default/files/registre_francais_de_la_mucoviscido se_-_bilan_2015_v4.pdf 2 New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther, pp.19-34, 2015.

K. Frayman, D. Armstrong, R. Carzino, T. Ferkol, K. Grimwood et al., The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis, Cystic Fibrosis: Microbiology and Host Response, 2009.
DOI : 10.1136/thoraxjnl-2016-209279

R. Gibson, J. Burns, and B. Ramsey, Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.8, pp.918-51, 2003.
DOI : 10.1164/rccm.200304-505SO

M. Alhede, T. Bjarnsholt, M. Givskov, and M. Alhede, Pseudomonas aeruginosa Biofilms, Adv Appl Microbiol, vol.86, pp.1-40, 2014.
DOI : 10.1016/B978-0-12-800262-9.00001-9

C. Cigana, N. Lorè, M. Bernardini, and A. Bragonzi, Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa Pneumonia, J Biomed Biotechnol, pp.852513-852522, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00975374

C. Winstanley, O. Brien, S. Brockhurst, and M. , Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections, Trends in Microbiology, vol.24, issue.5, pp.327-364, 2016.
DOI : 10.1016/j.tim.2016.01.008

URL : http://doi.org/10.1016/j.tim.2016.01.008

J. Govan and V. Deretic, Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev, 1996.

D. Krieg, R. Helmke, V. German, and J. Mangos, Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro, Infect Immun, vol.56, issue.12, pp.3173-3182, 1988.

N. Høiby, O. Ciofu, and T. Bjarnsholt, biofilms in cystic fibrosis, WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf [Internet], pp.1663-74, 2010.
DOI : 10.2217/fmb.10.125

H. Johansen and P. Gøtzsche, Available from: http://www.who.int/medicines/publications/WHO-PPL- Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1 15 Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis, Cochrane Database Syst Rev, issue.8, pp.1399-1415, 2015.

G. Priebe and J. Goldberg, Vaccines for Pseudomonas aeruginosa, Expert Rev Vaccines. 2014, vol.13, issue.4, pp.507-526
DOI : 10.1007/978-1-4615-0053-7_17

S. Worgall, 40 years on: have we finally got a vaccine for Pseudomonas aeruginosa? Future Microbiol, pp.1333-1338, 2012.
DOI : 10.2217/fmb.12.106

G. Döring and G. Pier, Vaccines and immunotherapy against Pseudomonas aeruginosa, Vaccine, vol.26, issue.8, pp.1011-1035, 2008.
DOI : 10.1016/j.vaccine.2007.12.007

K. Grimwood, J. Kyd, S. Owen, H. Massa, and A. Cripps, infection, Human Vaccines & Immunotherapeutics, vol.67, issue.1, pp.14-20, 2015.
DOI : 10.1128/IAI.74.2.968-974.2006

I. Delany, R. Rappuoli, D. Gregorio, E. Sharma, A. Krause et al., Vaccines for the 21st century Recent developments for Pseudomonas vaccines. Hum Vaccin, 22. Pier GB. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen, pp.708-728, 2003.

S. Hanessian, W. Regan, D. Watson, and T. Haskell, Isolation and Characterization of Antigenic Components of a New Heptavalent Pseudomonas Vaccine, Nature New Biology, vol.229, issue.7, pp.209-219, 1971.
DOI : 10.1038/newbio229209a0

G. Döring, C. Meisner, M. Stern, M. Blanks, and D. Wozniak, A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients, Proceedings of the National Academy of Sciences, vol.1, issue.8996, pp.11020-11025, 2006.
DOI : 10.1016/S0140-6736(96)90442-0

L. Wu, O. Estrada, O. Zaborina, M. Bains, L. Shen et al., Recognition of Host Immune Activation by Pseudomonas aeruginosa, Science, vol.309, issue.5735, pp.774-781, 2005.
DOI : 10.1126/science.1112422

J. Staczek, L. Gilleland, H. Van-der-heyde, and H. Gilleland, DNA vaccines against chronic lung infections by Pseudomonas aeruginosa, FEMS Immunol Med Microbiol Jul, vol.1537, pp.2-3147, 2003.
DOI : 10.1016/s0928-8244(03)00075-0

T. Sawa, T. Yahr, M. Ohara, K. Kurahashi, M. Gropper et al., Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury, Nat Med, vol.5, issue.4, pp.392-400, 1999.

S. Worgall, A. Krause, M. Rivara, K. Hee, E. Vintayen et al., Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid, Journal of Clinical Investigation, vol.115, issue.5, pp.1281-1290, 2005.
DOI : 10.1172/JCI23135

A. Cripps, K. Peek, M. Dunkley, K. Vento, J. Marjason et al., Safety and Immunogenicity of an Oral Inactivated Whole-Cell Pseudomonas aeruginosa Vaccine Administered to Healthy Human Subjects, Infection and Immunity, vol.74, issue.2, 2006.
DOI : 10.1128/IAI.74.2.968-974.2006

I. Lin, T. Van, and P. Smooker, Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery, Vaccines, vol.58, issue.4, pp.940-72, 2015.
DOI : 10.1016/S0168-3659(01)00340-6

URL : http://doi.org/10.3390/vaccines3040940

C. Locht and N. Mielcarek, Live attenuated vaccines against pertussis, Expert Review of Vaccines, vol.13, issue.9, pp.1147-58, 2014.
DOI : 10.1586/14760584.2014.942222

G. Priebe, G. Meluleni, F. Coleman, J. Goldberg, and G. Pier, Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant, Infection and Immunity, vol.71, issue.3, pp.1453-61, 2003.
DOI : 10.1128/IAI.71.3.1453-1461.2003

W. Wu, J. Huang, B. Duan, D. Traficante, H. Hong et al., Pneumonia, American Journal of Respiratory and Critical Care Medicine, vol.186, issue.5, pp.420-427, 2012.
DOI : 10.1164/rccm.201202-0182OC

G. Priebe, R. Walsh, T. Cederroth, A. Kamei, Y. Coutinho-sledge et al., IL-17 Is a Critical Component of Vaccine-Induced Protection against Lung Infection by Lipopolysaccharide-Heterologous Strains of Pseudomonas aeruginosa, The Journal of Immunology, vol.181, issue.7, pp.4965-75, 1950.
DOI : 10.4049/jimmunol.181.7.4965

S. Wollowitz, Fundamentals of the psoralen-based Helinx? technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, Seminars in Hematology, vol.38, issue.4, pp.4-11, 2001.
DOI : 10.1016/S0037-1963(01)90118-0

T. Dubensky, J. Skoble, P. Lauer, and D. Brockstedt, Killed but metabolically active vaccines, Current Opinion in Biotechnology, vol.23, issue.6, pp.917-940
DOI : 10.1016/j.copbio.2012.04.005

K. Bruhn, R. Birnbaum, J. Haskell, V. Vanchinathan, S. Greger et al., Killed but Metabolically Active Leishmania infantum as a Novel Whole-Cell Vaccine for Visceral Leishmaniasis, Clinical and Vaccine Immunology, vol.19, issue.4, pp.490-498
DOI : 10.1128/CVI.05660-11

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318268

J. Skoble, J. Beaber, Y. Gao, J. Lovchik, L. Sower et al., Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax, Infection and Immunity, vol.77, issue.4, pp.1649-63, 2009.
DOI : 10.1128/IAI.00530-08

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663168

L. Gouëllec, A. Chauchet, X. Laurin, D. Aspord, C. Verove et al., A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy, Molecular Therapy, vol.21, issue.5, pp.1076-86, 2013.
DOI : 10.1038/mt.2013.41

L. Gouëllec, A. Chauchet, X. Polack, B. Buffat, L. Toussaint et al., Bacterial vectors for active immunotherapy reach clinical and industrial stages. Hum Vaccines Immunother, pp.1454-1462, 2012.

X. Chauchet, D. Hannani, S. Djebali, D. Laurin, B. Polack et al., Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery, Molecular Therapy - Oncolytics, vol.3, p.16033, 2016.
DOI : 10.1038/mto.2016.33

URL : https://hal.archives-ouvertes.fr/hal-01463683